News Headlines

  1. US-China Trade War Offers Window Of Opportunity For Indian Pharma Sector, Says GlobalData

    The ongoing US-China retaliatory trade war, under which both the governments are slapping punitive tariffs on various imported products from each other, provides a window of opportunity for the Indian pharma firms to penetrate the Chinese healthcare market and reduce trade deficit, says leading data and analytics company GlobalData.

  2. China Drug Regulator Calling On International Pharmaceutical Companies To Bring 'Urgently Needed' New Drugs To China

    On 8 August 2018, in an unprecedented regulatory action, China National Drug Administration (CNDA) (formerly known as CFDA) called on international pharmaceutical companies to bring 48 new drugs to China.

  3. FDA Approves First-Of-Its Kind Targeted RNA-Based Therapy To Treat A Rare Disease

    The U.S. Food and Drug Administration recently approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

  4. MilliporeSigma’s BioReliance® Product Characterization Services Help Ensure Purity, Safety And Efficacy

    MilliporeSigma has launched its BioReliance® Product Characterization Portfolio of tests for quality assessment of biologic drugs. This new, comprehensive suite of tests, provides critical information that biologic manufacturers need as they design their production process.

  5. Turkish Pharmaceutical Industry Leader, Abdi Ibrahim, Selects rfxcel For FMD Compliance

    Abdi Ibrahim, the Turkish pharmaceutical industry leader, has carefully selected rfxcel to implement and support new compliance management and serialisation processing software to ensure full compliance with current and future international legislative requirements ahead of the 2019 EU Falsified Medicines Directive (FMD) deadline.

  6. Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island

    Amgen today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus.

  7. Ex-Biogen And MIT Exec Launch Writeinteractive To Solve 'Documentation Crisis'

    A long-time Boston-area entrepreneur and technical writer recently announced the formation of Writeinteractive, Inc. The start-up plans to help companies address the myriad of challenges associated with producing technical documentation in-house, especially for those in regulated industries.

  8. Almac Group Launches GMP High Throughput Peptide Manufacturing Service

    Almac Group, the global contract development and manufacturing organisation, is delighted to announce the successful MHRA registration of its High Throughput GMP Peptide manufacturing facility. Based at the Technopole campus near Edinburgh, Scotland, the facility manufactures neoantigen derived peptides for use in the production of patient specific, individualised cancer vaccines.

  9. WuXi STA’s Jinshan Site Passes Fourth U.S. FDA Inspection

    STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announces that its Active Pharmaceutical Ingredient (API) manufacturing facility at Jinshan (Shanghai, China) has successfully passed its fourth inspection from the U.S. Food and Drug Administration (USFDA) – with no Form 483s issued. The site previously passed three FDA inspections in 2013, 2014 and 2016.

  10. Gilead Sciences Announces CEO John F. Milligan To Step Down

    Gilead Sciences, Inc. announced todaythat John F. Milligan, PhD, will step down as President and Chief Executive Officer after a 28-year career with the company. Dr. Milligan will remain in his current position through the end of the year, while the Board of Directors conducts a search to identify a successor.